Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Review
.2015 Jul;21(7):730-8.
doi: 10.1038/nm.3897. Epub 2015 Jun 29.

Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies

Affiliations
Review

Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies

Judy H Cho et al. Nat Med.2015 Jul.

Abstract

Recent advances in genome-wide association studies (GWAS) across autoimmune and immune-mediated diseases have augmented our understanding of pathogenic mechanisms underlying these diseases. This has further highlighted their heterogeneous nature, both within and between diseases. Furthermore, varying responses to therapy have also served to underline the importance of this heterogeneity in the manner in which these diseases are diagnosed and treated. Here we discuss our current understanding of the shared pathways of autoimmunity, including the tumor necrosis factor (TNF), major histocompatibility complex (MHC), interleukin 23 receptor (IL23R) and protein tyrosine phosphatase non-receptor type 22 (PTPN22) pathways. In addition, we summarize effective specific therapies tested across major autoimmune diseases, highlighting the insight they have provided into disease mechanisms and their implications for potential future improvements.

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the online version of the paper.

Figures

Figure 1
Figure 1
Timeline of pathogenicity and therapeutic interventions in autoimmune diseases. Altered immune function antedates disease presentation across autoimmune diseases. In some cases, most notably for type 1 diabetes, substantial structural damage has already occurred by the time of disease presentation. In such cases, therapeutic options are restricted to symptomatic treatment, such as hormone replacement (insulin, thyroid hormones). For many other autoimmune diseases, therapeutic paradigms involve earlier treatment, control of inflammation and prevention of structural damage. In the future, induction of immune tolerance, and normalization of immune function may be accomplished, guided by genetic stratification for both treatment and prevention of disease.
Figure 2
Figure 2
Levels of therapeutic targeting across autoimmunity. Targetable pathways of rheumatoid arthritis and psoriasis are shown. Therapies that are effective in rheumatoid arthritis are shown in red, and therapies effective in psoriasis are shown in blue. The broad efficacy of anti-TNF therapy across many diseases reflects its central role in the cytokine network. In contrast, a more limited range of diseases have demonstrated positive results to blockade with anti–IL-12/23. IL-23 perpetuates and stabilizes IL23R-expressing pathogenic cells, including CD4+ TH17 cells. IL-17, as produced by TH17 cells, promotes neutrophilia, as well as enhances antimicrobial defense and tissue repair. Antagonism of IL6R and CTLA4 fusion proteins preventing CD28 co-stimulation are effective in the treatment of rheumatoid arthritis, as are B cell ablation approaches, such as by CD20-specific antibody administration, which are approved for the treatment of rheumatoid arthritis.
See this image and copyright information in PMC

References

    1. Hradetzky S, et al. The human skin-associated autoantigen alpha-NAC activates monocytes and dendritic cells via TLR-2 and primes an IL-12-dependent Th1 response. J Invest Dermatol. 2013;133:2289–2292. - PubMed
    1. Harlow L, Fernandez I, Soejima M, Ridgway WM, Ascherman DP. Characterization of TLR4-mediated auto-antibody production in a mouse model of histidyl-tRNA synthetase-induced myositis. Innate Immun. 2012;18:876–885. - PubMed
    1. Kopp P. The TSH receptor and its role in thyroid disease. Cell Mol Life Sci. 2001;58:1301–1322. - PMC - PubMed
    1. Ross GL, Barland P, Grayzel AI. The immunoglobulin class of anti-DNA antibodies: detection by a fluorometric immunoassay: clinical and pathological correlations in SLE. J Rheumatol. 1978;5:373–383. - PubMed
    1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373:659–672. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2026 Movatter.jp